- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02990078
Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury
October 10, 2022 updated by: Ramon Diaz-Arrastia, University of Pennsylvania
Cerebrovascular Reactivity Assessed With Functional Near-infrared Spectroscopy as a Biomarker of Traumatic Microvascular Injury After Moderate-severe Traumatic Brain Injury
The investigators will longitudinally measure cerebrovascular reactivity (CVR) by functional near-infrared spectroscopy (fNIRS) in acute (≤3 days from injury), subacute, and chronic phases after TBI as a biomarker of TCVI as compared to healthy controls.
CVR will be measured by fNIRS response to hypercapnia.
The investigators hypothesize that CVR will be decreased after TBI and that these decreases will correlate with clinical outcomes.
Furthermore, the investigators predict that administration of a vasodilatory medication (sildenafil) will augment CVR after TBI.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
26
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Penn Presbyterian Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Male and female, aged 18 or older, presenting with a diagnosis of traumatic brain injury (TBI) and healthy peer control volunteers .
Description
Inclusion Criteria:
- Men and women, aged ≥18
CT evidence of TBI-linked abnormality
- Traumatic subarachnoid hemorrhage
- Intracerebral hemorrhage/contusion
- Subdural/epidural hematoma
- Ability to undergo fNIRS testing with hypercapnia challenge
- Subject able to provide informed consent
- Attending of record agrees to include subject in study
Exclusion Criteria:
- Unstable respiratory or hemodynamic status
- Evidence of penetrating brain injury
- TBI requiring craniotomy or craniectomy
- Evidence or risk of ICP crisis
- History of disabling pre-existing neurologic disorder (e.g. dementia, uncontrolled epilepsy, multiple sclerosis, strokes, brain tumors, prior severe TBI, or other disorder that confounds interpretation of NIRS testing or neuropsychological results)
- History of pre-existing disabling mental illness (e.g. major depression or schizophrenia)
Exclusion criteria for sildenafil administration:
- History of melanoma
- current use of organic nitrate vasodilators
- current use of ritonavir (HIV-protease inhibitor)
- current use of erythromycin, ketoconazole, or itraconazole; current use of cimetidine
- current use of alpha-blockers such as doxazosin (Cardura), tamsulosin (Flomax), and terazosin (Hytrin) prazosin (Minipres)
- resting hypotension (systolic BP <90)
- severe renal insufficiency
- hepatic cirrhosis
- acute ischemic stroke within past 2 months
- acute myocardial infarction within past 2 months
- unstable angina pectoris
- acute or chronic heart failure
- retinitis pigmentosa
- pregnant or breastfeeding female
- known hypersensitivity or allergy to sildenafil
- Unstable cardiac status that constitutes a contraindication to sexual activity
- Inability to read and communicate in English (necessary to obtain reliable neuropsychometric data)
- Nursing mothers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Acute TBI
Subjects will be recruited from the neurointensive care unit within 72 hours of their injury.
At the time of informed consent, the investigators will perform fNIRS testing with a hypercapnia challenge, fNIRS with hypercapnia challenge 60 minutes after a single oral dose of 50mg sildenafil citrate, outcome qustionaires and symptom checklists (including: Glasgow Outcomes Scale-Extended, Rivermead Post-Concussive Symptom Questionnaire, Brief Symptom Inventory, Alcohol Consumption Questionnaire, Patient Health Questionnaire, and Insomnia Severity Index).
This will all be administered again at 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, and 4 years after injury.
|
Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina.
Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication.
In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR.
Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth.
The investigators have an IND exemption for the uses in this study.
Other Names:
Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity.
are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues.
The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
Other Names:
The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange.
It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired.
For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject.
The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
|
Sub-acute/Chronic TBI
Subjects who suffered a TBI previously and have now entered a subacute or chronic phase of their TBI will be approached by the research team at their clinic visit with a TBI specialist.
In those subjects, study timing will be based on the time of their original injury, therefore will start study visits at the next possible time point.
|
Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina.
Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication.
In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR.
Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth.
The investigators have an IND exemption for the uses in this study.
Other Names:
Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity.
are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues.
The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
Other Names:
The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange.
It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired.
For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject.
The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
|
Healthy Controls
The investigators will also enroll healthy "peer controls".
These control subjects will be family members and friends of TBI subjects.
These peer controls are likely to have similar environmental and socioeconomic exposures/support which may impact recovery after TBI and may also impact CVR.
These control subjects will meet the same inclusion/exclusion criteria as TBI subjects without the requirement for an injury or acute brain imaging.
These subjects will be tested in the same way as both TBI groups, but will only have one visit.
|
Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina.
Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication.
In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR.
Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth.
The investigators have an IND exemption for the uses in this study.
Other Names:
Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity.
are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues.
The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
Other Names:
The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange.
It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired.
For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject.
The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in CVR prior to sildenafil administration
Time Frame: < 72hrs, 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, 4 years
|
< 72hrs, 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, 4 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change CVR after sildenafil administration
Time Frame: <72 hours, 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, 4 years
|
<72 hours, 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, 4 years
|
Relationship of CVR with symptom reports, as measured by the Neurobehavioral Symptom Inventory (NBSI).
Time Frame: < 72hrs, 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, 4 years
|
< 72hrs, 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, 4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ramon Diaz-Arrastia, MD, PhD, University of Pennsylvania Perelman School of Medicine, Department of Neurology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 1, 2016
Primary Completion (ACTUAL)
June 30, 2022
Study Completion (ACTUAL)
September 30, 2022
Study Registration Dates
First Submitted
December 5, 2016
First Submitted That Met QC Criteria
December 7, 2016
First Posted (ESTIMATE)
December 12, 2016
Study Record Updates
Last Update Posted (ACTUAL)
October 13, 2022
Last Update Submitted That Met QC Criteria
October 10, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Brain Injuries
- Brain Injuries, Traumatic
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Sildenafil Citrate
Other Study ID Numbers
- 825942
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on TBI
-
Power Life Sciences Inc.Not yet recruiting
-
Lara McKenzieCompleted
-
VA Office of Research and DevelopmentCompleted
-
San Diego Veterans Healthcare SystemCongressionally Directed Medical Research ProgramsCompletedPTSD With a History of Mild to Moderate TBIUnited States
-
Kessler FoundationNew Jersey Commission on Brain Injury ResearchCompletedMotor Learning in TBIUnited States
-
ElMindA LtdAthletico Physical TherapyCompletedMinor Traumatic Brain Injury (TBI)United States
-
VA Office of Research and DevelopmentNot yet recruitingCognitive Dysfunction | TBIUnited States
-
ElMindA LtdNoran Neurological ClinicCompletedHealthy | Minor Traumatic Brain Injury (TBI)United States
-
Sheba Medical CenterRecruitingTraumatic Brain Injury (TBI) PatientsIsrael
-
ElMindA LtdYork UniversityCompletedMinor Traumatic Brain Injury (TBI)Canada
Clinical Trials on Sildenafil citrate
-
Northwestern UniversityCompletedHand Foot Skin ReactionUnited States
-
University of PennsylvaniaWalter Reed National Military Medical CenterRecruiting
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
University of Mississippi Medical CenterActive, not recruiting
-
Pfizer's Upjohn has merged with Mylan to form Viatris...No longer availablePulmonary Arterial HypertensionIndia
-
Federal University of São PauloUniversity of Sao PauloCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedScleroderma, Systemic | Scleroderma, Diffuse | Raynaud Phenomenon | Scleroderma, LimitedBrazil